Combination antidiabetic agent (biguanide + DPP-4 inhibitor)

This page covers all Combination antidiabetic agent (biguanide + DPP-4 inhibitor) drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Metformin: mitochondrial glycerophosphate dehydrogenase; Vildagliptin: DPP-4 (dipeptidyl peptidase-4), SGLT2 transporter, mitochondrial complex I (metformin), dipeptidyl peptidase-4, AMP-activated protein kinase (metformin); serotonin and norepinephrine transporters (sibutramine).

Targets

Metformin: mitochondrial glycerophosphate dehydrogenase; Vildagliptin: DPP-4 (dipeptidyl peptidase-4) · SGLT2 transporter, mitochondrial complex I (metformin), dipeptidyl peptidase-4 · AMP-activated protein kinase (metformin); serotonin and norepinephrine transporters (sibutramine) · AMPK (metformin); folate receptors and methylenetetrahydrofolate reductase (folic acid) · Multiple: AMPK pathway (metformin), PPAR-γ (pioglitazone), GLP-1 receptor (exenatide) · Metformin: AMP-activated protein kinase (AMPK) pathway; Sulfonylureas: ATP-sensitive potassium channel (KATP) · Pioglitazone: PPAR-γ; Metformin: AMPK · Norepinephrine transporter (NET), serotonin transporter (SERT); AMP-activated protein kinase (AMPK) · Metformin: AMP-activated protein kinase (AMPK) pathway; Yasmin: progesterone receptor and estrogen receptor · Metformin: AMP-activated protein kinase (AMPK) pathway; Rosuvastatin: HMG-CoA reductase

Marketed (7)

• MET + Vildagliptin Group · Hospital de Clinicas de Porto Alegre · Diabetes
  This combination uses metformin to reduce hepatic glucose production and improve insulin sensitivity, while vildagliptin inhibits DPP-4 to increase incretin-mediated insulin secretion and reduce glucagon.
• SGLT2i+Metformin+Linagliptin · Huazhong University of Science and Technology · Diabetes
  This triple-combination therapy reduces blood glucose through three complementary mechanisms: blocking renal glucose reabsorption (SGLT2i), enhancing insulin secretion and sensitivity (metformin), and inhibiting dipeptidyl peptidase-4 to prolong incretin action (linagliptin).
• metformin+sibutramine · Promomed, LLC · Endocrinology / Diabetes
  Metformin reduces hepatic glucose production and improves insulin sensitivity, while sibutramine suppresses appetite by inhibiting reuptake of serotonin and norepinephrine, together addressing hyperglycemia and weight management in type 2 diabetes.
• Metformin plus folic acid · University Magna Graecia · Endocrinology / Diabetes
  Metformin reduces hepatic glucose production and improves insulin sensitivity, while folic acid serves as a methyl donor and cofactor for nucleotide synthesis.
• metformin\pioglitazone\exenatide · The University of Texas Health Science Center at San Antonio · Diabetes
  This triple-agent combination improves blood glucose control through three complementary mechanisms: metformin reduces hepatic glucose production, pioglitazone increases insulin sensitivity in muscle and fat, and exenatide stimulates insulin secretion in response to glucose.
• metformin or sulfonylurea · Dr. Milan Gupta · Diabetes
  Metformin decreases hepatic glucose production and improves insulin sensitivity, while sulfonylureas stimulate pancreatic beta cells to increase insulin secretion.
• Pioglitazone vs Metformin · Post Graduate Institute of Medical Education and Research, Chandigarh · Endocrinology / Diabetes
  This is a comparative analysis of two marketed diabetes drugs: pioglitazone (a thiazolidinedione that increases insulin sensitivity) versus metformin (a biguanide that reduces hepatic glucose production and improves insulin sensitivity).

Phase 3 pipeline (3)

• Sibutramine-Metformin · Laboratorios Silanes S.A. de C.V. · Endocrinology / Obesity / Diabetes
  Sibutramine-Metformin is a combination drug that suppresses appetite through norepinephrine reuptake inhibition while improving insulin sensitivity and glucose metabolism.
• Metformin plus Yasmin · Catholic University of the Sacred Heart · Endocrinology / Contraception
  This combination pairs metformin, which reduces hepatic glucose production and improves insulin sensitivity, with Yasmin (drospirenone/ethinyl estradiol), a hormonal contraceptive, to address both glycemic control and contraceptive needs in women with diabetes or prediabetes.
• Metformin + Rosuvastatin · Jeil Pharmaceutical Co., Ltd. · Endocrinology / Cardiovascular
  This combination reduces blood glucose through metformin's inhibition of hepatic glucose production and increases insulin sensitivity, while rosuvastatin lowers cholesterol by inhibiting HMG-CoA reductase.

Patent intelligence

• antidiabetic agent patent landscape — aggregated cliff calendar, attackable patents, originator estates